HAYS ROAD BRIDGE. IT'' S SHOWING UP AT 6:00. >> > > Ursula: CMT IS NAMED AFTER THE THREE PHYSICIANS FROM ENGLAND AS WELL AS FRANCE THAT FIRST DEFINED IT EVEN MORE THAN 100 YEARS AGO. IT'' S A HEREDITARY PROBLEM THAT CREATES PROBLEMS WITH SENSORY AS WELL AS ELECTRIC MOTOR NERVES AS WELL AS FOR SOME THE PROGRESSION IS SO SEVERE THEY BECOME MOBILITY DEVICE BOUND. BUT THERE IS A NEW TREATMENT THAT MAY HALT CMT IN ITS TRACKS. 21-YEAR-OLD DAKOTA RILEY HAS HAD PROBLEMS WITH HER FEET FOR ALMOST HALF HER LIFE. >> > > I COULDN ' T RUN ANYMORE AND I DID HAVE PROBLEM WALKING BUT I HAD THE MENTALITY OF I'' M SIMPLY GOING TO PERFORM WHATEVER I CAN UP UNTIL I PHYSICALLY CAN'' T DO IT ANY LONGER. >> > > Ursula: DAKOTA WAS DIAGNOSED WITH A CONDITION THAT RESULTS IN DETERIORATED MUSCLES UNDER OF THE FEET.
>> > > WHEN THEY ARE WALKING THEIR FOOT IS DANGLING DOWN AS WELL AS THEY ARE NOT ABLE TO RAISE IT. >> > > Ursula: AS DAKOTA'' S CONDITION GOT WORSE, FOUR SURGICAL PROCEDURES ENABLED HER TO STROLL WITHOUT BRACES AND ALSO START COLLEGE AT THE NEW YORK CITY FASHION INSTITUTE OF MODERN TECHNOLOGY. >> >'> I ' M SO HAPPY WITH HER. SHE'' S THRIVING AND ALSO SHE ' S DOING INCREDIBLY WELL. I MEAN, SHE HAS SO MUCH STRUGGLE EVERYDAY AND SHE SIMPLY MAINTAINS GOING. >> > > Press Reporter: KAREN RILEY OFFERS ON THE BOARD O THE GENETIC NEUROPATHY STRUCTURE AND ALSO IS FOLLOWING TESTING OF A BRAND-NEW DRUG. IF APPROVED BY THE FDA IT IS SAID TO STOP THE PROGRESSION AND POSSIBLY RETURN A SMALL PERCENTAGE OF WHAT WAS LOST.
>> > > Ursula: IT'' S A MIXES OF 3 MEDICATIONS THAT ARE CURRENTLY AUTHORIZED FOR UNASSOCIATED CONDITIONS. IN EARLIER TRIAL RUN, PEOPLE REVEALED SUBSTANTIAL ENHANCEMENT. DAKOTA WAS NOT IN THE TEST BECAUSE SHE HAS A LESS COMMON FORM OF CMT, BUT KAREN STATED SHE REALLY HOPES HER DAUGHTER WILL PROFIT FROM THE DRUG WHEN IT'' S ACCEPTED. >> > > IT WOULD MODIFICATION HER LIFE. >> > > Ursula: THAT MEDICATION REMAINS IN STAGE 3 CLINICAL TESTS NOW, WHICH IS THE LAST.
